Retreatment of Hepatitis C Virus Among People Who Inject Drugs
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf082 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Aurielle M Thomas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Clinical Research, University of Rhode Island, Kingston, Rhode Island, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Hepatitis C, Chronic, Substance Abuse, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Gilead Sciences, Quest Diagnostics, Monogram Biosciences.
Abstract (Originalsprache)
Background
Hepatitis C virus (HCV) is a leading cause of infectious disease death in the United States. Although highly effective direct-acting antiviral (DAA) regimens are well established, retreatment among people who inject drugs (PWID) has not been sufficiently studied. This study assessed DAA retreatment outcomes and associated factors.
Methods
We performed analyses of longitudinal data from the HERO Study, a US-based multi-site pragmatic randomized trial conducted in 8 states to evaluate effectiveness of 2 HCV care models among DAA treatment-naïve PWID in opioid treatment programs and community clinics. After initial HERO Study sofosbuvir/velpatasvir (SOF/VEL) treatment, participants eligible for retreatment were identified, from 15 September 2016 to 13 September 2021. This analysis characterizes participants who either did not achieve sustained virologic response (SVR) or were reinfected with HCV post-SVR. We compared categorical variables using Fisher exact test and continuous variables using the Welch 2 sample t test for means and an asymptotic 2-sample Mood median test.
Results
One hundred four participants were identified as eligible for retreatment. Less than half, 43 (41.3%), initiated retreatment. Among the 25 who initiated retreatment and for whom SVR results were available, 24 achieved SVR (96%). Participants who did not achieve SVR initiated retreatment more promptly than participants reinfected post-SVR (respectively, 471 vs 784 days on average, P < .001).
Conclusions
After reinfection or not achieving SVR with the first DAA regimen, retreated PWID achieved higher SVR rates than with initial DAA treatment. To attain HCV elimination and benefit individual and public health, assisting PWID with accessing prompt retreatment is crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Clinical Research, University of Rhode Island, Kingston, Rhode Island, USA.
- Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
- Department of Medicine at Prisma Health, Clemson University School of Health Research, Clemson, South Carolina, USA.
- Department of Medicine, University of South Carolina School of Medicine, Greenville, South Carolina, USA.
- Department of Medicine, Prisma Health, Greenville, South Carolina, USA.
- Division of General Internal Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Alain H Litwin, Judith I Tsui, Sophie Sprecht-Walsh, Karen T Tashima, Judith Feinberg, Kimberly Page, Shruti H Mehta, Brianna L Norton, Moonseong Heo, Cristina Murray-Krezan, Julia Arnsten, Megan Groome, Lynn E Taylor
Förderung
- Gilead Sciences
- Quest Diagnostics
- Monogram Biosciences
- OraSure Technologies
- Patient-Centered Outcomes Research Institute
Zitieren
APA
Thomas, A. M., Litwin, A. H., Tsui, J. I., Sprecht-Walsh, S., Blalock, K. L., Tashima, K. T., Lum, P. J., Feinberg, J., Page, K., Mehta, S. H., Kim, A. Y., Norton, B. L., Heo, M., Stein, E. S., Murray-Krezan, C., Arnsten, J., Groome, M., Waters, E., & Taylor, L. E. (2025). Retreatment of Hepatitis C Virus Among People Who Inject Drugs. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf082
Vancouver
Thomas AM, Litwin AH, Tsui JI, Sprecht-Walsh S, Blalock KL, Tashima KT, et al. Retreatment of Hepatitis C Virus Among People Who Inject Drugs. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf082
BibTeX
@article{Thomas2025,
author = {Thomas, Aurielle M and Litwin, Alain H and Tsui, Judith I and Sprecht-Walsh, Sophie and Blalock, Kendra L and Tashima, Karen T and Lum, Paula J and Feinberg, Judith and Page, Kimberly and Mehta, Shruti H and Kim, Arthur Y and Norton, Brianna L and Heo, Moonseong and Stein, Ellen S and Murray-Krezan, Cristina and Arnsten, Julia and Groome, Megan and Waters, Emily and Taylor, Lynn E},
title = {Retreatment of Hepatitis C Virus Among People Who Inject Drugs},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf082}
}
EUVIMED